Recent U.S. models estimate that from 2020 to 2025, routine albumin-to-creatinine ratio testing combined with targeted nutritional interventions could prevent chronic kidney disease progression in about 1.3 million patients, reducing medical costs by roughly $16 billion (114). The gene discussed is ALB; the disease is chronic kidney disease.